Electrocardiographic Features of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy According to Disease Severity

Nasir, Khurram; Bomma, Chandra; Tandri, Harikrishna; Roguin, Ariel; Dalal, Darshan; Prakasa, Kalpana; Tichnell, Crystal; James, Cynthia A.; Jspevak, Phillip; Marcus, Frank I.; Calkins, Hugh

doi:10.1161/01.cir.0000142293.60725.18

Cited by 255 publications

(68 citation statements)

References 17 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a pathological myocardial substrate, this can perpetuate the incidence of life-threatening arrhythmias. Other studies have suggested that up to 67% of individuals with ARVC present with palpitations, 32% present with syncope, 27% with atypical chest pain, 6% with right ventricular failure, and 6% may remain asymptomatic [22]. …”

Section: Diagnosis Of Arvcmentioning

confidence: 99%

“…The management of ARVC is focused on prevention of lethal events such as SCD [21,22]. High-risk groups with an increased risk of SCD should be identified.…”

Section: Management Of Arvcmentioning

confidence: 99%

“…Despite the lack of evidence, decreasing the sympathetic activity might decrease SCD. BB has been used in ARVC patients with VA, supra-VT, or atrial fibrillation/flutter with high-ventricular rate (class I) [22]. BB can be useful in patients with symptomatic ARVC regardless of arrhythmias (class IIa) [22].…”

Section: Beta-blockersmentioning

confidence: 99%

“…BB has been used in ARVC patients with VA, supra-VT, or atrial fibrillation/flutter with high-ventricular rate (class I) [22]. BB can be useful in patients with symptomatic ARVC regardless of arrhythmias (class IIa) [22]. Most common symptoms for which BB can be helpful in ARVC patients include lightheadness, shortness of breath, and palpitations (class IIa) [22].…”

Section: Beta-blockersmentioning

confidence: 99%

“…Most common symptoms for which BB can be helpful in ARVC patients include lightheadness, shortness of breath, and palpitations (class IIa) [22]. However, BB is not recommended for an asymptomatic healthy patient with gene carriers (Class III) [22]. …”

Section: Beta-blockersmentioning

confidence: 99%

See 4 more Smart Citations

Right ventricular dysplasia: management and treatment in light of current evidence

Idris

Shah

Park

2018

Journal of Community Hospital Internal Medicine Perspectives

View full text Add to dashboard Cite

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare cardiovascular disease that predisposes to ventricular arrhythmias potentially leading to sudden cardiac death (SCD). ARVC varies considerably with multiple clinical presentations, ranging from no symptoms to cardiac arrhythmias to SCD. ARVC prevalence is not well known, but the estimated prevalence in the general population is 1:5000. Diagnosis of ARVC can be made by using the Revised European Society of Cardiology criteria for ARVC that includes ventricular structural and functional changes, ECG abnormalities, arrhythmias, family and genetic factors. The management of ARVC is focused on prevention of lethal events such as SCD. Implantable cardioverter defibrillator placement is the only proven mortality benefit in treatment of ARVC. Other treatment strategies include medications such as beta blockers and antiarrhythmics, radiofrequency ablation, surgery, cardiac transplantation, and lifestyle changes. All these interventions help in symptomatic treatment but none of them have proved to decrease mortality rates. ARVC is a progressive disease that leads to SCD if not treated appropriately. Management of these diseases has been a challenge for physicians. With the advent of technology and many new drugs/devices under clinical investigation, this might change in the future. However, while advances in technologies have helped elucidate many aspects of these diseases, many mysteries still remain of this unique disease. With continued research, we can expect more cost-effective and patient-friendly drug therapies and ablation techniques to be developed in the near future.

show abstract

Section: Diagnosis Of Arvcmentioning

confidence: 99%

“…The management of ARVC is focused on prevention of lethal events such as SCD [21,22]. High-risk groups with an increased risk of SCD should be identified.…”

Section: Management Of Arvcmentioning

confidence: 99%

Section: Beta-blockersmentioning

confidence: 99%

Section: Beta-blockersmentioning

confidence: 99%

Section: Beta-blockersmentioning

confidence: 99%

See 3 more Smart Citations

Right ventricular dysplasia: management and treatment in light of current evidence

Idris

Shah

Park

2018

Journal of Community Hospital Internal Medicine Perspectives

View full text Add to dashboard Cite

show abstract

Combined Endocardial and Epicardial Mapping of Ventricular Tachycardia

Hutchinson¹,

Marchlinski²

2012

Cardiac Mapping

View full text Add to dashboard Cite

Ventricular Arrhythmias

Waleffe

Piérard²

2017

Practical Cardiovascular Medicine

View full text Add to dashboard Cite

Air pollution has been associated with ventricular arrhythmias in patients with implantable cardioverter defibrillators (ICDs) for exposure periods of 24-48 h. Only two studies have investigated exposure periods ,24 h. We aimed to explore such effects during the 2 and 24 preceding hours as well as in relation to distance from the place of the event to the air pollution monitor. Methods and results We used a case-crossover design to investigate the effects of particulate matter ,10 mm in diameter (PM 10) and nitrogen dioxide (NO 2) in 211 patients with ICD devices in Gothenburg and Stockholm, Sweden. Events interpreted as ventricular arrhythmias were downloaded from the ICDs, and air pollution data were collected from urban background monitors. We found an association between 2 h moving averages of PM 10 and ventricular arrhythmia [odds ratio (OR) 1.31, 95% confidence interval (CI) 1.00-1.72], whereas the OR for 24 h moving averages was 1.24 (95% CI 0.87-1.76). Corresponding ORs for events occurring closest to the air pollution monitor were 1.76 (95% CI 1.18-2.61) and 1.74 (95% CI 1.07-2.84), respectively. Events occurring in Gothenburg showed stronger associations than in Stockholm. Conclusion Moderate increases in air pollution appear to be associated with ventricular arrhythmias in ICD patients already after 2 h, although future studies including larger numbers of events are required to confirm these findings. Representative geographical exposure classification seems important in studies of these effects.

show abstract

Electrocardiographic Features of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy According to Disease Severity

Cited by 255 publications

References 17 publications

Right ventricular dysplasia: management and treatment in light of current evidence

Right ventricular dysplasia: management and treatment in light of current evidence

Combined Endocardial and Epicardial Mapping of Ventricular Tachycardia

Ventricular Arrhythmias

Contact Info

Product

Resources

About